Viewing Study NCT00175513



Ignite Creation Date: 2024-05-05 @ 11:55 AM
Last Modification Date: 2024-10-26 @ 9:16 AM
Study NCT ID: NCT00175513
Status: COMPLETED
Last Update Posted: 2011-04-14
First Post: 2005-09-11

Brief Title: V3 Vancouver-Victoria Valacyclovir Trial for Early Psychosis
Sponsor: University of British Columbia
Organization: University of British Columbia

Study Overview

Official Title: V3 Vancouver-Victoria Valacyclovir Trial for Early Psychosis
Status: COMPLETED
Status Verified Date: 2011-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This is an 18 week 2 weeks run-in 16 weeks double blind trial to determine if an antiviral drug valacyclovir Valtrex is helpful in treating the symptoms of psychosis a form of a mental disorder
Detailed Description: There is evidence that some of the symptoms of psychosis may be related to past infection with common viruses

Researchers are looking to recruit a total of 100 subjects with evidence in the past of exposure to at least 1 of 3 viruses The viruses include herpes type 1 HSV-1 which causes cold sores of the lip and has affected about 610 people in Vancouver herpes type 2 HSV-2 which causes genital sores and has affected less than 110 people in Vancouver and cytomegalovirus CMV which causes few symptoms but has affected 810 people in Vancouver People who have been infected with these viruses in the past develop antibodies in the blood The antibodies can be measured in blood and are a test of whether or not there was infection in the past and possibly affecting the symptoms of psychosis

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
TPD 094295 None None None
FHA 2005-07 None None None